\
&
Contact us
\
&
Contact us
The rules for project implementation are set-out in a Grant Agreement. NCP Flanders guides and supports you with all legal and financial issues during the complete life cycle of Horizon Europe.
All specific Legal&Finance news, documents, events, ...regarding Horizon 2020 can be found on the dedicated Horizon 2020 page on our website.
The administrative and financial framework with the rules for application and project implementation of Horizon Europe calls are set-out in a Grant Agreement. The latest draft of the Annotated Model Grant Agreement provides extensive explanation of the rules.
In the Online Manual extensive details can be found regarding the application process as well as the Grant Management, thus in-depth explanations about reporting, amendments, deliverables, dissemination&exploitation, etc. The manual is expected to be complemented throughout the programming period.
All available reference documents of Horizon Europe can be found on the Funding and Tender Portal.
ann.vanhauwaert@fwo.be
+32 2 550 15 60
Ria.debreucker@vlaio.be
+32 2 553 13 77
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
